Cerhum

What we do: Cerhum is a Belgian medical technology company specializing in the development of patient-specific, 3D-printed bioceramic bone grafts and implants. Their flagship product, MyBone® Custom, is designed to replace traditional bone grafts with a highly osteoconductive, porous structure that promotes rapid vascularization and bone ingrowth. These implants are used primarily in maxillofacial, dental, and orthopedic surgeries to treat severe facial deformities caused by trauma, congenital conditions, or cancer, as well as to support dental implants where bone loss is an issue.

Location: Cerhum is headquartered at Rue des Pôles 1, 4000 Liège, Belgium. The company operates from this Belgian base, maintaining strong academic partnerships, notably with the University of Liège.

History: Founded in 2016 as a spinout from Sirris, the Belgian national Science and Technology Institute, Cerhum has rapidly advanced the field of maxillofacial surgery by developing innovative 3D-printed bioceramic implants. To date, Cerhum has produced over 10,000 synthetic bone grafts used in orthopedic implants and has successfully passed all regulatory approvals for clinical use in Europe.

Organization & culture: Cerhum employs a dedicated team of 22 collaborators. The company culture is built on integrity, innovation, and teamwork, fostering an environment where every voice is valued and innovative ideas can thrive. Cerhum positions itself not just as a medical device company but as a pioneer committed to continuous improvement in healthcare.

Recent developments: Cerhum’s MyBone® implant has been approved for patient use across Europe, demonstrating seven times faster bone ingrowth compared to existing bone graft granules. The company is expanding its portfolio into dental and oncological markets, with ongoing preclinical trials and clinical discussions to validate new applications.